


*IPW*

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
(MBHB Case No. 02-742-E; 400/130)**



**In the Application of:**

**McSwiggen et al.**

**Serial No.: 10/664,668**

**Filing Date: September 18, 2003**

**For: RNA Interference of Mediated Inhibition  
Of Vascular Endothelial Growth Factor  
And Vascular Endothelial Growth Factor  
Receptor Gene Expression Using Short  
Interfering Nucleic Acid (siNA)**

**Examiner: TBA**

**Group Art Unit: 1635**

**Confirmation No. 5711**

Commissioner of Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450


Sir:

**TRANSMITTAL LETTER**

In regard to the above identified application:

1. We are transmitting herewith the attached papers for the above identified new patent application:
  - Second Supplemental Information Disclosure Statement;
  - Second Supplemental Information Disclosure Statement (IDS) PTO/SB/08B Form;
  - Copies of IDS Citations for S/N 10/664,668 (Total 7 other documents); and
  - Return Receipt Postcard.
2. With respect to additional fees, no additional fee is required.
3. GENERAL AUTHORIZATION: Please charge any additional fees or credit overpayment to Deposit Account No. 13-2490. A duplicate copy of this sheet is enclosed.
4. CERTIFICATE OF MAILING UNDER 37 CFR § 1.8: The undersigned hereby certifies that this Transmittal Letter and the paper, as described in paragraph 1 hereinabove, are being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450 on 10/30 2006.

By :

  
**Lisa M.W. Hillman**  
**Registration No. 43,673**



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
(MBHB Case No. 02-742-E; 400/130)**

**PATENT**

**In the Application of:**

<b>McSwiggen et al.</b>	)	
<b>Serial No.: 10/664,668</b>	)	<b>Examiner: TBA</b>
<b>Filing Date: September 18, 2003</b>	)	<b>Group Art Unit: 1635</b>
<b>For: RNA Interference of Mediated Inhibition Of Vascular Endothelial Growth Factor And Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering Nucleic Acid (siNA)</b>	)	<b>Confirmation No. 5711</b>

**SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. Section 1.97 - 1.99, the Applicant wishes to make the following references of record in the above-identified application. This Second Supplemental Information Disclosure Statement is in compliance with the continuing duty of candor as set forth in 37 C.F.R. Section 1.56. Copies of the cited references are enclosed. These references are also listed on the enclosed PTO/SB/08B form.

The Office has amended the requirement under 37 CFR 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. patent applications. See 69 Fed. Reg. 56481. In accordance with this amendment, cited U.S. patents and U.S. patent application publications are not enclosed.


In the judgment of the undersigned, portions of the listed references may be material to the Examiner's consideration of the presently pending claims. This statement is not a representation that the listed references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. Section 102 or Section 103.

Applicants do not believe any fee is due with this submission. If this belief be in error and the Patent Office determines that the fee prescribed in the relevant portion of 37 C.F.R. Section 1.97 is applicable, the undersigned attorney by his signature hereby authorizes any such fee to be debited from Deposit Account 13-2490.

Respectfully submitted,  
**McDonnell Boehnen Hulbert & Berghoff LLP**

Date: 10 / 30, 2006

By:



**Lisa M.W. Hillman**  
Registration No. 43,673

**McDonnell Boehnen Hulbert & Berghoff LLP**  
300 South Wacker Drive, 32<sup>nd</sup> Floor  
Chicago, IL 60606  
Telephone: 312-913-0001  
Facsimile: 312-913-0002

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

NOV 02 2006

**SECOND SUPPLEMENTAL  
INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
*(Use as many sheets as necessary)*

Sheet	1	of	2	Attorney Docket Number	02-742-E (400/130)
-------	---	----	---	------------------------	--------------------

**Complete if Known**

Application No.	10/664,668
Filing Date:	September 18, 2003
First Named Inventor	McSwiggen et al.
Art Unit	1635
Examiner Name	unassigned

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
A	US-5,587,471		12-1996	Cook et al.	
B	US-5,916,763		06-1999	Wiliams et al.	
C	US-6,710,174		03-23-2004	Bennett et al.	
D	US-2003/0186920		10-2003	Sirois, Martin G.	
E	US-2003/0216335		11-2003	Lockridge et al.	
F	US-2004/0018176		01-2004	Tolentino et al.	
G	US-2004/0209832		10-2004	McSwiggen et al.	

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
1	Caplen, Nathan, "RNAi as a gene therapy approach, " <i>Expert Opin. Biol. Ther.</i> 3(4):575-586 (2003)		
2	Hammond, et al., "Post-transcriptional Gene Silencing by Double-Stranded RNA," <i>Nature Reviews</i> , 2:110-119 (2001)		
3	Mahato et al., "Modulation of gene expression by antisense and antogene oligodeoxynucleotides and small interfering RNA," <i>Expert Opin. Drug Deliv.</i> , 2(1):3-28 (2005)		
4	Scherer et al., "Approaches for the sequence-specific knockdown of mRNA," <i>Nature Biotechnology</i> , 21:12, 1457-1465 (2003)		
5	Schmidt et al., "Base and sugar requirements for RNA cleavage of essential nucleoside residues in internal loop B of the hairpin ribozyme: implications for secondary structure," <i>Nucleic Acids Research</i> 24:573-581 (1996)		

Examiner Signature		Date Considered
--------------------	--	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO				<b><i>Complete if Known</i></b>	
<b>SECOND SUPPLEMENTAL</b> <b>INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				Application No.	10/664,668
Filing Date:				September 18, 2003	
First Named Inventor				McSwiggen et al.	
Art Unit				1635	
Examiner Name				unassigned	
Sheet	2	of	2	Attorney Docket Number	02-742-E (400/130)

	6	Vickers et al., "Efficient Reduction of Target RNAs by Small Interfering RNA and RNase H-dependent Antisense Agents," <i>The Journal of Biological Chemistry</i> , 278:9, 7108-7118 (2003)	
	7	Zhang et al., "Targeted Gene Silencing by Small Interfering RNA-based Knock-Down Technology," <i>Current Pharmaceutical Biotechnology</i> , 5, 1-7 (2004)	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.